Nanotechnology for diagnosis and therapy of idiopathic pulmonary fibrosis: Recent advances and future perspectives
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Idiopathic pulmonary fibrosis
2. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis10.1136/bmj-2021-066354 ↗
3. Idiopathic pulmonary fibrosis10.1136/thoraxjnl-2011-200515 ↗
4. Idiopathic pulmonary fibrosis: an update on pathogenesis
5. Fibroblast to myofibroblast transition is enhanced by increased cell density10.1091/mbc.E20-08-0536 ↗
6. Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems10.1016/j.phymed.2020.153298 ↗
7. EMT and interstitial lung disease: a mysterious relationship
8. Precision Medicine advances in idiopathic pulmonary fibrosis10.1016/j.ebiom.2023.104766 ↗
9. Early diagnosis and treatment of idiopathic pulmonary fibrosis: a narrative review10.1007/s41030-023-00216-0 ↗
10. Idiopathic pulmonary fibrosis and the role of genetics in the era of precision Medicine
11. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis10.1146/annurev-pathol-042320-030240 ↗
12. Idiopathic pulmonary fibrosis: state of the art for 202310.1183/13993003.00957-2022 ↗
13. Interstitial lung disease: a review10.1001/jama.2024.3669 ↗
14. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline10.1164/rccm.202202-0399ST ↗
15. ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis, an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management10.1164/rccm.2009-040GL ↗
16. Lung cell transplantation for pulmonary fibrosis
17. Nintedanib: a review in fibrotic interstitial lung diseases10.1007/s40265-021-01487-0 ↗
18. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis10.1183/16000617.0057-2017 ↗
19. Current and future treatment landscape for idiopathic pulmonary fibrosis10.1007/s40265-023-01950-0 ↗
20. Idiopathic pulmonary fibrosis (IPF): diagnostic routes using novel biomarkers10.1016/j.bj.2024.100729 ↗
21. Fluorescent carbon Nano-onion as bioimaging probe10.1021/acsabm.0c01192 ↗
22. Pulmonary delivery of nano-particles for lung cancer diagnosis and therapy: recent advances and future prospects
23. Nanoparticle-Based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases10.1021/acs.molpharmaceut.1c00491 ↗
24. Health impact and toxicological effects of nanomaterials in the lung10.1111/j.1440-1843.2012.02171.x ↗
25. Nanotechnology based therapeutics for lung disease10.1136/thoraxjnl-2019-213037 ↗
26. Emerging delivery approaches for targeted pulmonary fibrosis treatment10.1016/j.addr.2023.115147 ↗
27. The application and prospects of drug delivery systems in idiopathic pulmonary fibrosis10.1016/j.bioadv.2024.214123 ↗
28. Recent advances in nanogels for drug delivery and biomedical applications10.1039/D4BM00224E ↗
29. Controlled pulmonary drug and gene delivery using polymeric nano-carriers10.1016/j.jconrel.2011.12.004 ↗
30. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies10.1016/j.biomaterials.2019.119491 ↗
31. Targeting senescent alveolar epithelial cells using engineered mesenchymal stem Cell-Derived extracellular vesicles to treat pulmonary fibrosis10.1021/acsnano.3c10547 ↗
32. Cobalt protoporphyrin-induced nano-self-assembly for CT imaging, magnetic-guidance, and antioxidative protection of stem cells in pulmonary fibrosis treatment
33. Gas exchange and ventilation-perfusion relationships in the lung10.1183/09031936.00037014 ↗
34. Pulmonary applications and toxicity of engineered nanoparticles10.1152/ajplung.00041.2008 ↗
35. Regeneration or repair? The role of alveolar epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF)10.3390/cells11132095 ↗
36. Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis10.1164/rccm.202004-1274OC ↗
37. Contributions of alveolar epithelial cell quality control to pulmonary fibrosis10.1172/JCI139519 ↗
38. Tracing the origin of alveolar stem cells in lung repair and regeneration10.1016/j.cell.2024.03.010 ↗
39. The history and mystery of alveolar epithelial type II cells: focus on their physiologic and pathologic role in lung10.3390/ijms22052566 ↗
40. Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis10.3390/ijms21072269 ↗
41. Type 2 alveolar cells are stem cells in adult lung10.1172/JCI68782 ↗
42. Regulation of epithelial transitional states in murine and human pulmonary fibrosis10.1172/JCI165612 ↗
43. Nebulized inhalation of nintedanib-loaded biomimetic nano-liposomes attenuated bleomycin-induced interstitial lung fibrosis in mice10.1016/j.nantod.2024.102298 ↗
44. Inflammation and immunity in IPF pathogenesis and treatment10.1016/j.rmed.2018.12.015 ↗
45. Irreversibility of pulmonary fibrosis10.14336/AD.2021.0730 ↗
46. In primary airway epithelial cells, the unjamming transition is distinct from the epithelial-to-mesenchymal transition10.1038/s41467-020-18841-7 ↗
47. Idiopathic pulmonary fibrosis10.1016/S0140-6736(17)30866-8 ↗
48. Idiopathic pulmonary fibrosis: disease mechanisms and drug development10.1016/j.pharmthera.2020.107798 ↗
49. IPF: new insight on pathogenesis and treatment10.1111/j.1398-9995.2009.02305.x ↗
50. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions10.1111/crj.12190 ↗
51. Telomere-mediated lung disease10.1152/physrev.00046.2021 ↗
52. Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling10.1183/09059180.00010905 ↗
53. Spatially distinct molecular patterns of gene expression in idiopathic pulmonary fibrosis10.1186/s12931-023-02572-6 ↗
54. Telomere abnormalities in the pathobiology of idiopathic pulmonary fibrosis10.3390/jcm8081232 ↗
55. The relationship between MUC5B promoter, TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort
56. KLF4 regulates TERT expression in alveolar epithelial cells in pulmonary fibrosis10.1038/s41419-022-04886-7 ↗
57. Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis10.1152/ajpcell.00302.2023 ↗
58. Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-κB activation10.1111/acel.12858 ↗
59. Human bronchial epithelial cell-derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGF-β-WNT crosstalk
60. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis10.1016/j.apsb.2021.07.023 ↗
61. Chronic WNT/β-catenin signaling induces cellular senescence in lung epithelial cells10.1016/j.cellsig.2020.109588 ↗
62. Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-β and the Ubiquitin-Proteasome pathway10.3390/ijms22116107 ↗
63. Developmental pathways in the pathogenesis of lung fibrosis10.1016/j.mam.2018.08.004 ↗
64. Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis10.1186/s12967-024-05655-0 ↗
65. Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis
66. TGF-β-induced α-SMA expression is mediated by C/EBPβ acetylation in human alveolar epithelial cells10.1186/s10020-021-00283-6 ↗
67. Pulmonary fibrosis: from pathogenesis to clinical decision-making10.1016/j.molmed.2023.08.010 ↗
68. Bufei huoxue capsule alleviates bleomycin-induced pulmonary fibrosis in mice via TGF-β1/Smad2/3 signaling10.1016/j.jep.2023.116733 ↗
69. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis10.1183/09031936.00174914 ↗
70. Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment10.1186/s12890-023-02565-7 ↗
71. Translating idiopathic pulmonary fibrosis guidelines into clinical practice10.1016/j.pulmoe.2020.05.017 ↗
72. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?10.1183/09059180.00004914 ↗
73. An efficient electrochemical assay for miR-3675-3p in human serum based on the nanohybrid of functionalized fullerene and metal-organic framework10.1016/j.aca.2020.10.017 ↗
74. A microdroplet SERS-RCA biosensor with enhanced specificity and reproducibility for profiling dual miRNAs in idiopathic pulmonary fibrosis diagnosis and monitoring10.1016/j.cej.2024.149012 ↗
75. MR imaging, targeting and characterization of pulmonary fibrosis using intra-tracheal administration of gadolinium-based nanoparticles10.1002/cmmi.1703 ↗
76. GSH-Responsive drug delivery system for active therapy and reducing the side effects of bleomycin10.1021/acsami.1c21828 ↗
77. A Manganese(II) complex as high-order multiphoton fluorescent probe for detecting nitric oxide content change in idiopathic pulmonary fibrosis mice10.1016/j.snb.2023.134437 ↗
78. A DNA octahedral amplifier for endogenous circRNA detection and bioimaging in living cells and its biomarker study10.1039/D3AN01803B ↗
79. Q.-L. Li, X. Chang, Y.-M. Han, Z.-C. Guo, Y.-N. Liu, B. Guo, C. Liu, B.-R. Yang, Z.-K. Fan, H.-L. Jiang, X. Chang, Consumption of Endogenous Caspase-3 Activates Molecular Theranostic Nanoplatform against Inflammation-Induced Profibrotic Positive Feedback in Pulmonary Fibrosis, Advanced Science n/a (n.d.) 2412303. https://doi.org/10.1002/advs.202412303.10.1002/advs.202412303 ↗
80. Multimodal feature fusion machine learning for predicting chronic injury induced by engineered nanomaterials10.1038/s41467-025-58016-w ↗
81. MRI of the lung: state of the art
82. MRI of the lung (2/3). why … when … how?10.1007/s13244-011-0146-8 ↗
83. Gadolinium-induced acute respiratory distress syndrome: a rare clinical entity10.4103/mamcjms.mamcjms_6_23 ↗
84. The safety of magnetic resonance imaging contrast agents10.3389/ftox.2024.1376587 ↗
85. Polydopamine-based nanostructures: a new generation of versatile, multi-tasking, and smart theranostic tools10.1016/j.nantod.2024.102151 ↗
86. Bleomycin-induced lung injury in mice investigated by MRI: model assessment for target analysis10.1002/mrm.23009 ↗
87. Molecular magnetic resonance imaging of pulmonary fibrosis in mice10.1165/rcmb.2013-0039OC ↗
88. Fluorescent-based nanosensors for selective detection of a wide range of biological macromolecules: a comprehensive review10.1016/j.ijbiomac.2022.02.137 ↗
89. Biomarkers and their potential functions in idiopathic pulmonary fibrosis10.1080/17476348.2020.1745066 ↗
90. Proteomic biomarkers of survival in idiopathic pulmonary fibrosis10.1164/rccm.202301-0117OC ↗
91. Recent advances on nanomaterials-based fluorimetric approaches for microRNAs detection10.1016/j.msec.2019.110007 ↗
92. Smart” nanoprobes for visualization of tumor microenvironments10.1002/adhm.201800391 ↗
93. Plasma vascular endothelial growth factor concentration and alveolar nitric oxide as potential predictors of disease progression and mortality in idiopathic pulmonary fibrosis10.3390/jcm5090080 ↗
94. Evaluation of nitric oxide fluctuation via a fast, responsive fluorescent probe in idiopathic pulmonary fibrosis cells and mice models10.1021/acs.analchem.1c05643 ↗
95. Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis10.1016/j.niox.2019.05.001 ↗
96. Biomarkers and molecular probes for cell death imaging and targeted therapeutics10.1021/bc3003309 ↗
97. circHIPK3 regulates lung fibroblast-to-myofibroblast transition by functioning as a competing endogenous RNA10.1038/s41419-019-1430-7 ↗
98. Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis
99. PET/CT-guided and OPN-targeted melanin nanoparticle platform for early diagnosis and precision therapy of idiopathic pulmonary fibrosis (IPF)10.1016/j.cej.2024.158140 ↗
100. Targeted imaging of pulmonary fibrosis by a cyclic peptide LyP-110.1038/s41598-024-78068-0 ↗